Iovance Biotherapeutics, Inc. (IOVA) Financial Statements
Iovance Biotherapeutics, Inc. (IOVA) reported trailing twelve-month revenue of $325.0M (up 34.5% year on year) and net income of -$289.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$296.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IOVAIovance Biotherapeutics, Inc.Follow IOVA — free
—
Price chart with a free account
- Market cap
- 6.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Revenue | 1.2 | 164.1 | 263.5 | 325.0 | |
| Gross profit | 0.2 | 70.8 | 90.3 | 157.3 | |
| Research & development | 333.2 | 276.2 | 300.3 | 267.7 | |
| Operating income | -460.6 | -395.3 | -403.4 | -301.3 | |
| Pre-tax income | -447.5 | -375.0 | -393.0 | -293.8 | |
| Income tax | -3.5 | -2.8 | -2.1 | -4.3 | |
| Net income | -444.0 | -372.2 | -391.0 | -289.5 | |
| Diluted EPS ($) | -1.89 | -1.28 | -1.09 | — | |
| Diluted shares (mn) | 235.1 | 289.9 | 357.3 | — |
USD millions · SEC XBRL
Iovance Biotherapeutics, Inc. — questions
- What is Iovance Biotherapeutics, Inc.'s revenue?
- $325.0M over the twelve months to 2026-06-30, up 34.5% year on year, from its 10-Q and 10-K filings.
- What is Iovance Biotherapeutics, Inc.'s net income?
- -$289.5M over the twelve months to 2026-06-30.
- What is Iovance Biotherapeutics, Inc.'s free cash flow?
- -$296.4M over the twelve months to 2026-06-30.
Every figure on this page comes from Iovance Biotherapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.